tetano
Editor, Senior Moderator
Drugs
. 2025 Sep 25.
doi: 10.1007/s40265-025-02242-5. Online ahead of print. Onradivir: First Approval
Arnold Lee[SUP] 1 [/SUP]
Affiliations
Onradivir ([SUP]®[/SUP], Anruiwei) is a small molecule RNA polymerase inhibitor that potently binds to the PB2 cap-binding domain of RNA polymerase to inhibit the replication of the influenza A virus. It was developed by Guangdong Raynovent Biotech and received its first approval in May 2025 in China based on results from the NCT04683406 phase III trial. This article summarizes the milestones in the development of onradivir leading to this first approval for the treatment of uncomplicated influenza A in adults, excluding those at high risk for influenza-related complications.
© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
. 2025 Sep 25.
doi: 10.1007/s40265-025-02242-5. Online ahead of print. Onradivir: First Approval
Arnold Lee[SUP] 1 [/SUP]
Affiliations
- PMID: 40996478
- DOI: 10.1007/s40265-025-02242-5
Onradivir ([SUP]®[/SUP], Anruiwei) is a small molecule RNA polymerase inhibitor that potently binds to the PB2 cap-binding domain of RNA polymerase to inhibit the replication of the influenza A virus. It was developed by Guangdong Raynovent Biotech and received its first approval in May 2025 in China based on results from the NCT04683406 phase III trial. This article summarizes the milestones in the development of onradivir leading to this first approval for the treatment of uncomplicated influenza A in adults, excluding those at high risk for influenza-related complications.
© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.